News
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. | Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy,
Hosted on MSN24d
Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threatswhile a representative for Novo Nordisk declined to comment. Trump, who is set to be inaugurated on Monday, has set a massive agenda for when he takes office. The future status of Greenland has ...
Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...
Novo Nordisk does expect a bit of pullback in growth ... positively due to its stance on Greenland. Just uncertainty on this front can be bad for the stock, and in the event of a negative ...
Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...
Novo Nordisk's head of commercial strategy steps ... Denmark welcomes US decision to skip Greenland dog-sled race amid Trump spat Denmark on Wednesday welcomed a U.S. decision to confine a ...
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 ...
Novo Nordisk (NVO) closed the most recent trading day at $69.30, moving -1.23% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.97%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback